GYRE — Gyre Therapeutics Inc.

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Gyre Therapeutics Inc.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$5.74
Market Cap$600M
Float21.3M
Shares Outstanding97.0M
P/E (Forward)78.13
Price/Sales (TTM)5.12
vs. Analyst Target+225.2% to analyst PT
Profit Margin-5.44%
Operating Margin (TTM)-30.21%
Revenue (TTM)$117M
Earnings Growth (YoY)166.20%
Dividend RateNone
Analyst Target Price$18.67 (1 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $20.9M -$55.5M $11.8M -$56.1M
2021 $7.3M -$87.9M -$332,000 -$87.6M
2022 $102M $2.3M $97.5M $10.3M
2023 $113M -$92.9M $109M $20.3M
2024 $106M $12.1M $102M $17.8M
2025 $117M $5.0M $111M $14.0M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $26.8M $442,000
Sep 2025 $30.6M $3.6M
Dec 2025 $37.2M -$1.7M
Mar 2026 $22.5M -$8.6M

Ownership & Float

Insider Ownership86.3%
Institutional Ownership3.8%
Short Float7.4%
% of All Funds Holding0.58%
Number of Funds Holding48

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$7.04Near-term / short-term trend
Weekly40-Week SMA$7.51Medium-term trend
Weekly80-Week SMA$8.56Cyclical trend (business cycle)
Weekly200-Week SMA$10.36Secular trend (multi-year)
Monthly10-Month SMA$7.45Near-term monthly trend
Monthly20-Month SMA$8.87Medium-term monthly trend
Monthly40-Month SMA$10.04Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$9.10 resistance 1.72x 10 months ago
$11.60 resistance 2.51x 13 months ago

Historical Earnings Reactions (81 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.55% -0.17% 38.27% 41.13% -6.75%
1 Day -0.20% -0.22% 48.15% 21.28% -15.91%
1 Week -1.28% -1.66% 39.51% 65.71% -57.61%
2 Weeks 0.48% -0.36% 44.44% 204.55% -59.42%
1 Month -0.53% -2.51% 40.00% 211.36% -59.04%

Next earnings: July 26, 2026 (57 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-6.2%40.0%20
Feb4.0%65.0%20
Mar-6.2%30.0%20
Apr1.6%50.0%20
May4.5%35.0%20
Jun-2.1%35.0%20
Jul16.6%45.0%20
Aug-0.1%50.0%20
Sep-7.8%35.0%20
Oct-2.2%50.0%20
Nov8.9%60.0%20
Dec4.1%50.0%20

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.24% 47.7% 949
Tuesday -0.18% 44.0% 1039
Wednesday 0.22% 46.8% 1038
Thursday -0.05% 45.5% 1019
Friday 0.21% 45.4% 1015

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 3.8%

Insider Transactions — Smart Summary

Total insider ownership: 86.3%

12-Month Insider Activity Summary

Total Filings6
Net Value-$494,840.12
Net Shares Change-12,873
% of Float-0.1%
C-Suite Filings6
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Ye Weiguo Chief Operating Officer -$385,733.594 4 4 sell
Luo Ying Chief Executive Officer -$82,927.443 1 N/A
Ma Songjiang President -$26,179.084 1 N/A

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-05-27 Ye Weiguo Chief Operating Officer -$40,055.25 Transaction at $3.42, now +67.8%
2026-05-22 Ye Weiguo Chief Operating Officer -$119,988 Transaction at $3.45, now +66.4%
2026-05-20 Ye Weiguo Chief Operating Officer -$52,428.728 Transaction at $3.56, now +61.1%
2026-05-18 Ye Weiguo Chief Operating Officer -$173,261.616 Transaction at $3.77, now +52.2%
2026-05-07 Luo Ying Chief Executive Officer -$82,927.443 Transaction at $8.04, now -28.6%
2025-05-29 Ma Songjiang President -$26,179.084 Transaction at $10.23, now -43.9%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Gyre Therapeutics Inc. (GYRE) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for GYRE on Trend Edge →